By Dipesh Uprety Dr. Siddhartha Devarakonda, a director of Thoracic Medical Oncology at the Swedish Cancer Institute, presented on Disparities and
Pathology’s Role in Diagnosing Disparities By: Dr. Srinivas Tantravahi At the Summit On Cancer Disparities conference, Dr. Kamran Mirza, Clinical Professor of
At The Summit on Cancer Health Disparities 2024, in the session titled “Best Practices in Serving LGBTQ+ Communities,” Nakita Venus (they/them) and
A Discussion on Inclusive Research and Community Engagement Author: Bowen He, MD At The Summit on Cancer Health Disparities 2024, Dr. Michele
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On April 5, 2024, the Food and Drug Administration granted accelerated approval forfam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi
By: Dr. Arya Mariam Roy Roswell Park Comprehensive Cancer Center What are immune checkpoint inhibitors? Immune checkpoint inhibitors are a type of
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On March 1, 2024, the U.S. Food and Drug Administration approved amivantamab- vmjw (Rybrevant, Janssen Biotech,
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The FDA gave its approval for the use of osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) alongside platinum-based
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 16, 2024, the U.S. Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi).
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 15, 2024, the U.S. Food and Drug Administration granted regular approval to tepotinib (Tepmetko)